Clinical Study of Bevacizumab Combined with Chemotherapy Regimen in the Treatment of Non-Small Cell Lung Cancer
Objective To explore the clinical effect of bevacizumab combined with chemotherapy regimen in the treatment of non-small cell lung cancer(NSCLC).Methods 66 NSCLC patients admitted to our hospital from June 2018 to June 2022 were randomly divided into routine group and combined group,with 33 cases in each group.The routine group was treated with chemotherapy regimen,and the combined group was treated with bevacizumab combined with chemotherapy regimen.The treatment effect,serum indicator level and quality of life of the two groups were compared.Results The total effective rate of treatment in the combined group was 72.73％,higher than 48.48％in the routine group(P＜0.05).After treatment,the serum CEA,CA125 and CYFRA21-1 levels of the combined group were lower than those in the routine group(P＜0.05).After treatment,the FACT-L score of the combined group was higher than that of the routine group(P＜0.05).Conclusions Bevacizumab combined with chemotherapy regimen in the treatment of NSCLC patients can significantly improve the clinical efficacy,reduce the serum CEA,CA125 and CYFRA21-1 levels,and improve the quality of life.
国家科技期刊平台
NSTL
万方数据
